32
Participants
Start Date
November 25, 2020
Primary Completion Date
August 13, 2021
Study Completion Date
August 13, 2021
TNM002 Dosage 1 (10 μg/kg)
TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
Placebo
placebo to match TNM002 Dosage 1, given once
TNM002 Dosage 2 (35 μg/kg)
TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
Placebo
placebo to match TNM002 Dosage 2, given once
TNM002 Dosage 3 (100 μg/kg)
TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
Placebo
placebo to match TNM002 Dosage 3, given once
TNM002 Dosage 4 (250 μg/kg)
TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
Placebo
placebo to match TNM002 Dosage 4, given once
Scientia Clinical Research, Sydney
TIGERMED AUSTRALIA PTY LIMITED
UNKNOWN
Zhuhai Trinomab Pharmaceutical Co., Ltd.
INDUSTRY